Business
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma
VAUGHAN, Ontario, March 23, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-month results from the pivotal U.S. clinical trial of the ELIOS System. Developed for the treatment of elevated intraocular pressure (IOP) in patients with open angle glaucoma, ELIOS is an implant-free procedure that uses next generation excimer laser technology. The ELIOS procedure is currently CE mar
About this update from Bausch + Lomb Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4152,"height":327,"url":"https://media.zenfs.com/en/business-wire.com/c006028960a39a3085e272d82520c586"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.JO7vMj95x7pcyZznxuYJw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTc2/https://media.zenfs.com/en/business-wire.com/c006028960a39a3085e272d82520c586","width":960,"height":76},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/fezy5J6zW6TkajKj_3jgiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xOTA-/https://media.zenfs.com/en/business-wire.com/c006028960a39a3085e272d82520c586","width":1200,"height":95}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Both primary effectiveness endpoints were met, demonstrating statistically significant and clinically meaningful intraocular pressure reduction.","length":144,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"ELIOS is an implant-free procedure that uses excimer laser technology for the treatment of glaucoma.","length":100,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Topline results will be discussed at 1:30 p.m. ET today on the inaugural Bausch + Lomb R&D Teach-in Webinar (register here).","length":128,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":372,"olType":false},{"type":"text","content":"VAUGHAN, Ontario, March 23, 2026--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-month results from the pivotal U.S. clinical trial of the ELIOS System. Developed for the treatment of elevated intraocular pressure (IOP) in patients with open angle glaucoma, ELIOS is an implant-free procedure that uses next generation excimer laser technology. The ELIOS procedure is currently CE marked in Europe and is under development and has not been reviewed by the FDA for safety and efficacy in the United States.","length":638,"tagName":"p"},{"type":"text","content":""These strong U.S. study results reinforce everything we’ve learned about ELIOS during the years it has been available in Europe," said Yehia Hashad, MD, executive vice president, R&D and chief medical officer, Bausch + Lomb. "Achieving mean...